TD Asset Management Inc Buys 27,860 Shares of Natera, Inc. $NTRA

Posted by on Jun 7th, 2026

TD Asset Management Inc boosted its stake in Natera, Inc. (NASDAQ:NTRA – Free Report) by 21.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 157,466 shares of the medical research company’s stock after purchasing an additional 27,860 shares during the period. TD Asset Management Inc owned about 0.11% of Natera worth $36,074,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of NTRA. Robinhood Asset Management LLC bought a new position in shares of Natera during the fourth quarter valued at $12,981,000. JPMorgan Chase & Co. raised its stake in shares of Natera by 9.4% during the third quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock valued at $1,871,914,000 after acquiring an additional 1,003,129 shares during the last quarter. Krilogy Financial LLC bought a new position in shares of Natera during the third quarter valued at $1,323,000. Zweig DiMenna Associates LLC raised its stake in shares of Natera by 6.8% during the third quarter. Zweig DiMenna Associates LLC now owns 132,500 shares of the medical research company’s stock valued at $21,329,000 after acquiring an additional 8,400 shares during the last quarter. Finally, Systrade AG bought a new position in shares of Natera during the fourth quarter valued at $11,454,000. Institutional investors own 99.90% of the company’s stock.

Natera Stock Down 3.1%

NTRA opened at $215.31 on Friday. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $256.36. The company has a fifty day moving average of $204.19 and a 200-day moving average of $216.06. The stock has a market cap of $30.83 billion, a PE ratio of -132.09 and a beta of 1.56.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Robert W. Baird set a $265.00 price target on shares of Natera in a research note on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Tuesday, April 21st. JPMorgan Chase & Co. raised their price target on shares of Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Wells Fargo & Company raised their price target on shares of Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Finally, Morgan Stanley decreased their price objective on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Natera currently has an average rating of “Moderate Buy” and a consensus target price of $256.12.

View Our Latest Analysis on NTRA

Insider Activity at Natera

In other news, Director Roelof Botha sold 78,000 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the completion of the sale, the director directly owned 1,076,198 shares in the company, valued at $237,097,181.38. This represents a 6.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 41,124 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the completion of the sale, the chief executive officer owned 108,743 shares of the company’s stock, valued at $24,035,465.29. The trade was a 27.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 156,530 shares of company stock valued at $33,914,062 over the last 90 days. 5.05% of the stock is owned by company insiders.

About Natera

(Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Read More

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.